Advancing Precision Diagnostics: Emerging Molecular Strategies for Early Detection and Control of Antimicrobial Resistance in 2026

Antimicrobial resistance (AMR) has emerged as one of the most serious threats to global public health, compromising the effectiveness of existing therapeutic options and increasing morbidity, mortality, and healthcare costs. Rapid and accurate detection of resistant pathogens is critical for guiding targeted treatment and limiting the unnecessary use of broad-spectrum antibiotics. Traditional culture-based antimicrobial susceptibility testing remains reliable but is constrained by lengthy processing times, which often delay clinical decision-making. Recent progress in molecular diagnostics has transformed the landscape of infectious disease detection. Technologies such as CRISPR-enabled biosensing, portable long-read sequencing platforms, and high-throughput metagenomic analysis combined with artificial intelligence now allow direct identification of pathogens and resistance determinants from clinical samples within a significantly reduced timeframe. These culture-independent approaches support timely precision therapy, strengthen hospital infection control, and enhance real-time resistance surveillance. As healthcare systems move toward data-driven clinical management in 2026, the integration of next-generation molecular diagnostics into routine practice will play a pivotal role in improving antimicrobial stewardship and mitigating the growing burden of AMR.